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Abstract
Context—Ozone exposure triggers airway inflammatory responses that may be influenced by
biologically active purine metabolites.
Objective—Examine the relationships between airway purine metabolites and established
inflammatory markers of ozone exposure, and determine if these relationships are altered in
individuals with atopy or asthma.
Materials and Methods—Mass spectrometry was utilized to measure concentrations of purine
metabolites (AMP, adenosine, hypoxanthine, uric acid) and non-purine metabolites (taurine, urea,
phenylalanine, tyrosine) in induced sputum obtained from 31 subjects with normal lung function
(13 healthy controls, 8 atopic non-asthmatics, and 10 atopic asthmatic) before and four hours after
ozone exposure.
Results—At baseline, the purines AMP and hypoxanthine correlated with multiple inflammatory
markers including neutrophil counts and the cytokines IL-6, IL-8, TNF-α, and IL-1β (r ranged
from 0.41–0.66, all p<0.05). Following ozone exposure, these purines remained correlated with
IL-6, IL-8, and TNF-α (r=0.37-0.68). However, AMP and hypoxanthine increased significantly
post ozone exposure in atopic nonasthmatics but not atopic asthmatics. In contrast, the non-purine
metabolite taurine correlated with baseline neutrophil counts (r=0.56) and IL-6 (r=0.53) and was
elevated post exposure in both atopic cohorts.
Discussion and Conclusions—The purine metabolites AMP and hypoxanthine are correlated
with multiple inflammatory markers at baseline and after ozone exposure. However, changes in
these purine metabolites after ozone appear to differ from other inflammatory markers, with less
response in atopic asthmatics relative to atopic nonasthmatics. Purine metabolites may play a role
in the signaling responses to ozone, but these responses may be altered in subjects with asthma.
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Ozone is a common environmental pollutant that has been strongly linked to increased
morbidity from respiratory diseases such as asthma and chronic obstructive pulmonary
disease (Ciencewicki et al., 2008). Exposure to ozone leads to oxidative stress that can
trigger inflammatory airway responses, including neutrophilic inflammation (Hollingsworth
et al., 2007). Recent evidence suggests that these inflammatory responses are enhanced in
sensitive individuals such as those with atopy or asthma (Hernandez et al., 2010).
Previous studies suggest that exposure to ozone is mediated through production of “danger
signals” of oxidative stress that lead to innate immune responses (Depuydt et al., 2002).
Interestingly, extracellular purines – biologically active molecules including ATP and its
metabolites – have also been shown to function as danger signals in response to a variety of
noxious stimuli (Bours et al., 2006). More directly, exposure of airway epithelial cells to
ozone has been shown to increase release of ATP into the extracellular space (Ahmad et al.,
2005). Furthermore, the purine metabolites that result from metabolism of this extracellular
ATP (Burnstock, 2006a) have also been linked to physiological pathways relevant to
oxidative stress responses. For example, AMP has been shown to correlate with markers of
neutrophilic airway inflammation (Loughlin et al., 2009, Esther et al., 2008a), which
increase in response to ozone exposure (Seltzer et al., 1986). Adenosine-mediated signaling
also influences a variety of inflammatory responses (Mohsenin and Blackburn, 2006), and
airway concentrations of this purine are elevated in stable asthmatic subjects (Huszar et al.,
2002, Esther et al., 2009, Loughlin et al., 2009, Driver et al., 1993) and are sensitive to
exacerbations and effective treatment (Csoma et al., 2005). Adenosine can be further
metabolized to hypoxanthine and uric acid, compounds that have also been linked to
responses to oxidative stress (Hee Sun et al., 2009), with uric acid a known activator of
inflammasomes (Gasse et al., 2009).
These findings suggest that purine metabolites may be involved in the response to ozone
exposure, and that purinergic responses might be enhanced in sensitive subjects with atopy
and/or asthma. To address these hypotheses, we examined sputum supernatants available
from a previously published study of ozone exposure in a group of subjects with normal
lung function that included healthy normal volunteers, atopic non-asthmatics, and atopic
asthmatics (Hernandez et al., 2010). These samples were analyzed using a mass
spectrometric method capable of measuring multiple purine metabolites including AMP,
adenosine, hypoxanthine, and uric acid. In addition, measurement of several non-purine
metabolites (urea, taurine, phenylalanine, tyrosine) for which mass spectrometric methods
have been established were included to assess whether observed relationships were specific
to purines. These non-purine metabolites included the sulfa-amino acid taurine that has




Subjects represented a subset of participants in a previously published study of ozone
exposure (13 healthy normal volunteers [NV], 8 atopic non-asthmatics with allergic rhinitis
[AR], and 10 atopic asthmatics [AA]) (Hernandez et al., 2010) in whom induced sputum
supernatants obtained before and after ozone exposure were available. As previously
described, the groups were defined on the basis of skin prick testing (atopic vs. nonatopic)
and methacholine challenge (asthmatic vs. non-asthmatic). All asthmatics also had a
physician diagnosis of mild intermittent asthma and were not on any long term controller
medication (inhaled corticosteroids or leukotriene receptor antagonist). Atopic subjects
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could utilize antihistamines or topical nasal steroids to control allergic rhinitis. All subjects
were free of respiratory symptoms for at least 4 weeks prior to the study. Demographic
features of these subjects are shown in Table 1. Each subject was exposed to 0.4 ppm ozone
for 2 hours while performing four 15 minute sessions of intermittent moderate exercise
separated by 15 minutes of seated rest. Sputum was obtained pre-exposure and again 4-6
hours post exposure. Methods for sputum induction and processing, lung function testing,
and assessing sputum cell counts and cytokine concentrations were as previously described
(Hernandez et al., 2010); the reference set for percent predicted lung function values was
from Knudson (Knudson et al., 1976). Samples were collected between April 2006 and
August 2009 and stored at −80 oC until analysis in October 2010. There were no significant
between group differences in time of storage, and no significant correlations were observed
between time of storage and concentrations of any metabolite.
Mass spectrometric analysis
Prior to analysis, a solution of isotopically labeled internal standards was added to each
sputum supernatant sample to a final concentration of 50 nM [13C, 15N] adenosine, 250 nM
[15N] AMP, and 50 μM [13C] urea plus the working concentration of an isotopically labeled
amino acid solution (NSK-A, Cambridge Isotope Laboratories, Inc., Andover, MA). Sample
plus internal standard was then filtered through a 10 kDa column for 30 minutes at 11,000 x
g at 4 degrees to remove macromolecules.
Mass spectrometry was performed using an liquid chromatography-tandem mass
spectrometry system with electrospray ionization interface including an Acquity solvent
manager and a TSQ-Quantum Ultra Triple Quadrupole Mass Spectrometer (Thermo, San
Jose). 5 μl of sample was injected onto an Atlantis T3 C18, 1.8 μm column (Waters, Milford
MA) operated with a methanol and 0.1% formic acid gradients as previously described
(Esther et al., 2008b). Mass spectrometric detection (Figure 1) was performed in multiple
reaction monitoring mode using appropriate transitions in mass-to-charge ratio (m/z) from
parent to product ion during tandem mass spectrometry for the purine metabolites AMP (m/z
transition 348→136), adenosine (268→136), hypoxanthine (135→92) and uric acid
(167→124) plus a select group of non-purine metabolites with which we have previous
experience including urea (61→44), taurine (124→80), phenylalanine (166→120), and
tyrosine (182→136). In addition, ion transitions were monitored for the isotopically labeled
AMP (353→141), adenosine (283→151), urea (62→45), phenylalanine (172→126), and
tyrosine (188→171) as internal standards. All ions were monitored in positive mode except
for hypoxanthine, uric acid and taurine, which were monitored in negative mode. Mass
spectrometric signal was defined as the ratio of the peak area of the metabolite divided by
the peak area of the relevant internal standard. Hypoxanthine and uric acid utilized the
adenosine internal standard, taurine the urea internal standard based on similar column run
times. Metabolite concentrations were determined by analysis of standard solutions run in
parallel.
All compounds were detected in all samples (Figure 1), except for one sample in which
taurine was below detection limits. In addition, 10 of the 62 samples analyzed (three healthy
control, two atopic non-asthmatic, five atopic asthmatic samples) exhibited extensive
degradation of the AMP internal standard (but not adenosine or other internal standards),
suggesting high ectonuclease activity. Because this high activity could alter concentrations
of both AMP and adenosine (the product of AMP hydrolysis), these samples were excluded
from analysis for adenosine and AMP.
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Data are presented as mean ± standard deviation. All sputa data were log transformed prior
to analysis to yield normalized datasets, as determined by the D'Agostino & Pearson
omnibus normality test. Correlations were determined using Pearson correlation coefficients.
Changes after ozone exposure were assessed using paired Student’s T-tests.
Results
Sputum supernatant samples obtained before and after ozone exposure were available from
31 subjects including 13 healthy controls, 8 atopic non-asthmatics, and 10 atopic asthmatics.
These subjects represented a subset of the subjects included in a previously published study
(Hernandez et al., 2010), and demographic characteristics in this subset were similar to those
of the larger group and did not exhibit any significant between group differences (Table 1).
Lung function as assessed by percent predicted FEV1 was within the normal range at
baseline but significantly decreased post ozone exposure in the group as a whole and in all
individual cohorts (Table 1). Sputum neutrophil counts (cells/mg) also increased after ozone
exposure when all subjects were combined (p<0.01), although increases observed within the
individual cohorts did not reach statistical significance. Of note, increases in neutrophil
counts post ozone exposure reached statistical significance in atopic non-asthmatic and
atopic asthmatic cohorts within the larger study (Hernandez et al., 2010).
Because several purine metabolites have been previously linked to inflammatory responses
(Burnstock, 2006b), the relationships between sputum purine metabolites and established
markers of inflammation were assessed. In the baseline, pre-exposure samples, the purine
metabolites AMP and hypoxanthine were significantly correlated with multiple markers of
inflammation including sputum neutrophil counts and the cytokines IL-1β, IL-6, IL-8, and
TNF-α (Table 2). In addition, adenosine was statistically significantly correlated with the
cytokines IL-6 and IL-8, with a correlation to neutrophil counts that did not reach statistical
significance (r=0.40, p=0.0504). In contrast, no significant correlations were observed
between uric acid and any inflammatory marker (not shown). Among the non-purine
metabolites, only taurine exhibited any significant correlation to inflammatory markers with
correlations to neutrophil counts and IL-6 (Table 2). Phenylalanine, tyrosine, and urea were
not correlated with any inflammatory marker (not shown).
In the sputum samples obtained post ozone exposure, the purine metabolites AMP and
hypoxanthine remained significantly correlated with the cytokines IL-6, IL-8, and TNF-α
(Table 2). Adenosine was not correlated with any inflammatory marker post ozone
exposure. Of the non-purine metabolites, taurine remained correlated with IL-6 and
exhibited a modest correlation with TNF-α. No purine or non-purine metabolite was
correlated with sputum neutrophil counts post ozone exposure, and the metabolites uric acid,
phenylalanine, tyrosine, and urea were not significantly correlated with any inflammatory
marker in these samples.
These data suggested that sputum concentrations of AMP and hypoxanthine, and to a lesser
extent adenosine and taurine, were significantly correlated with markers of inflammation
both before and after ozone exposure. Therefore, we examined whether exposure to ozone
altered concentrations of any of these metabolites comparable to the statistically significant
increases we observed in neutrophil counts (Table 1) and in the cytokines IL-6 (138±141 pg/
ml pre, 264±360 pg/ml post, p<0.05) and IL-8 (24.2±32.4 ng/ml pre, 35.9±46.4 ng/ml post,
p<0.05) within the group as a whole.. Interestingly, although we observed the predicted
increase in sputum taurine following ozone exposure (Table 2), changes in the purines AMP
and hypoxanthine did not reach statistical significance. Because our previous study
suggested that inflammatory responses to ozone are increased in subjects with atopy and/or
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asthma (Hernandez et al., 2010), we reexamined the data with the groups stratified by
cohort. In these evaluations, significant increases in AMP and hypoxanthine were observed
in the atopic nonasthmatics, but not healthy controls or atopic asthmatics (Figure 2A-C).
Overall, the magnitude of change in hypoxanthine was higher in atopic nonasthmatics
(increase of 0.24±0.22 log units) than in atopic asthmatics (-0.23±0.48 log units, p<0.05),
with similar pattern for AMP (increase of 0.34±0.31 log units atopic nonasthmatics,
0.00±0.29 log units atopic asthmatics) not reaching statistical significance (p=0.095). In
contrast, taurine increased significantly in both atopic nonasthmatic and atopic asthmatic
cohorts (Figure 2D), and the magnitude of change was similar in both atopic cohorts
(increase of 0.32±0.34 log units in atopic asthmatics, 0.23±0.28 log units in atopic
nonasthmatics, p=0.60). No statistically significant changes for any purine or non-purine
compound were observed in healthy normal volunteers, and no statistically significant
changes in adenosine (Figure 2B), uric acid, urea, phenylalanine, or tyrosine (not shown)
were observed in any cohort. Of note, we did not observe any statistically significant
differences in baseline pre- exposure metabolite concentrations, with an approximately ~0.2
log unit increase in the asthma cohort relative to the healthy controls not reaching statistical
significance (p=0.25).
Discussion
In this study, we observed that two purine metabolites – AMP and hypoxanthine –were
significantly correlated with multiple inflammatory markers that included neutrophil counts
and pro inflammatory cytokines both at baseline and following exposure to inhaled ozone.
These correlations were particularly robust for the cytokines IL-6 and IL-8, which have been
well established as biomarkers of ozone induced inflammation (Devlin et al., 1991, Jaspers
et al., 1997, Hernandez et al., 2010). Interestingly, although adenosine has also been linked
to ozone mediated inflammatory responses (particularly via IL-6) (Sun et al., 2008,
Sitaraman et al., 2001), the correlations between adenosine and inflammatory markers were
less robust than for other purine metabolites in this study. Similarly, no relationships were
observed between uric acid and inflammatory markers despite previous studies suggesting
that uric acid concentrations may influence inflammasome function (Gasse et al., 2009).
However, the samples obtained during this study reflected only a single, relatively early (4
hour) time point after ozone exposure, and it is possible that some relationships between
purine metabolites and ozone mediated inflammatory processes may be present at other time
frames. Furthermore, since subjects exercised during ozone exposure, we cannot rule out the
possibility that exercise contributed to the observed changes. However, we note that exercise
alone did not induce changes in sputum inflammatory markers in a previous, similar study
(Lay et al., 2007).
The correlations we observed between inflammatory markers and the purine metabolites
AMP and hypoxanthine are consistent with findings from previous studies. Correlations
between AMP and neutrophils have been observed in several studies of respiratory samples
(Esther et al., 2008a, Eltzschig et al., 2006, Loughlin et al., 2009), and elevated AMP
concentrations have been detected in airway samples from patients with cystic fibrosis, a
disease associated with significant neutrophilic airway inflammation (Esther et al., 2009,
Esther et al., 2008a). The mechanisms that underlie these relationships are not clear, but may
reflect release of ATP and accumulation of AMP directly by neutrophils (Lennon et al.,
1998, Chen et al., 2006). Indeed, ozone has been shown to trigger release of ATP from
airway epithelial cells (Ahmad et al., 2005), suggesting that the purine metabolites measured
in this study may be derived from metabolism of ATP. Unfortunately, the mass
spectrometric method used in this study was not sufficiently sensitive to measure ATP
directly. The relationships between hypoxanthine and airway inflammation have been less
well defined, but this purine metabolite is strongly linked to oxidative injury (Hee Sun et al.,
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2009) and has been found to be elevated in plasma and bronchoalveolar lavage fluid from
patients with acute respiratory distress syndrome (Quinlan et al., 1997).
Interestingly, while AMP and hypoxanthine were correlated with multiple inflammatory
markers before and after ozone exposure, statistically significant increases in these
metabolites after exposure to ozone were not observed within the group as a whole.
Examination of the group stratified by cohort suggested that the responses of hypoxanthine
(and likely AMP) were diminished in the atopic asthmatic cohorts relative to the atopic
nonasthmatics. This contrasts to our experience with other inflammatory markers, in which
the responses to ozone are generally enhanced in atopic asthmatics (Hernandez et al., 2010).
These findings suggest the possibility that the purinergic component of the response to
ozone may be reduced in the airways of subjects with atopic asthma relative to other atopic
individuals. If true, a reduced purinergic response to ozone in asthmatics would be
somewhat surprising, since several studies have demonstrated that airway adenosine
concentrations are elevated in asthmatic subjects (Huszar et al., 2002, Driver et al., 1993,
Loughlin et al., 2009) and increase after exposure to bronchoconstrictive stimuli such as
exercise or allergen (Csoma et al., 2005, Huszar et al., 2002, Vizi et al., 2002). However,
responses to ozone differ from those to other stimuli, with a more prominent neutrophilic
component in contrast to the predominant eosinophilic response to allergen (Ciencewicki et
al., 2008). Indeed, while adenosine has been identified as the primary purine altered in
asthma and other diseases, we did not observe changes in adenosine after ozone exposure in
the group as a whole or within any cohort, although this relatively small exploratory study
may have been insufficiently powered to detect these changes.
Purinergic signaling pathways are known to modulate inflammatory responses (Burnstock,
2006b), suggesting that the purinergic responses observed in this study may influence other
inflammatory cascades. In particular, adenosine mediated signaling has been shown to have
both positive and negative immunomodulatory effects (Vass and Horvath, 2008) which can
be mediated both by both adenosine present in extracellular fluid and by local generation of
adenosine from AMP via nuclease activity at epithelial surfaces (Eltzschig et al., 2006).
While adenosine mediated signaling alone tends to increase production of pro-inflammatory
cytokines such as IL-6 (Sun et al., 2008), increased concentrations of adenosine have also
been shown to attenuate release of IL-6 in response to other inflammatory stimuli such as
LPS (Hasko et al., 1996). Consistent with this observations, the atopic asthmatic group that
appeared to have decreased purinergic responses in this study also had the largest increase in
ozone stimulated IL-6 production in the larger study from which these samples were drawn
(Hernandez et al., 2010). While these associations between purines and other inflammatory
mediators are intriguing, more definitive elucidation of these relationships will require
further study.
It is feasible that the findings of this study are non-specific artifacts of the sample collection
or analytic methods. However, the fact that we did not observe correlations between
inflammatory markers and several non-purine metabolites (urea, phenylalanine, tyrosine)
argues against this hypothesis. Furthermore, the relationships between sputum taurine and
markers of inflammation are consistent with previous studies of this metabolite. Taurine is
found at high concentrations within human neutrophils (Fukuda et al., 1982), and elevated
sputum taurine concentrations have been observed to correlate with markers of inflammation
in CF patients (Witko-Sarsat et al., 1995). Thus, the relationships between sputum taurine
and neutrophil counts and its increase after ozone exposure are consistent with predictions
and lend further credence to the analytic methods used in this study.
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In summary, our study suggests that purine metabolites – particularly AMP and
hypoxanthine — are correlated with inflammatory markers of ozone exposure. However, the
analyses suggest the possibility that the purinergic component of the response to ozone may
be diminished in atopic asthmatics relative to other atopic individuals. While interesting,






TNF tumor necrosis factor
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Mass spectrometric chromatogram demonstrating detection of several purine metabolites
(left) and non-purine metabolites (right) from a sputum sample. The column run time for
each peak is shown.
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Concentrations pre (grey bars) and post (white bars) ozone exposure were analyzed for the
metabolites correlated with neutrophil counts in baseline samples: AMP (A), Ado (B),
hypoxanthine (C) and taurine (D). Significant increases after ozone exposure were noted for
AMP and hypoxanthine in the atopic nonasthmatics with allergic rhinitis (AR) but not the
atopic asthmatics (AA) or healthy normal volunteers (NV). In contrast, sputum taurine
increased significantly in both atopic groups. Data are shown a box-plots with whiskers as
defined by Tukey (1.5x the intraquartile range). * = p<0.05 pre vs. post, with analyses
performed on log-transformed mean values not depicted on the figure.
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Table 1
Demographic Characteristics and Response to Ozone
Demographics
All subjects Divided by Cohort
NV AR AA
 n= 31 13 8 10
 Age (years) 24.9 ± 5.6 23.7 ± 5.0 25.3 ± 5.4 26.1 ± 6.8
 Gender 16M/ 15F 6M/ 7F 5M/ 3F 5M/ 5F
 Race (% Caucasian) 64.5% 61.5% 62.5% 70.0%
 Body Mass Index (BMI) 26.2 ± 5.4 27.0 ± 6.1 26.2 ± 5.6 25.2 ± 4.6
Response to Ozone
All NV AR AA
 % predicted FEV1 – pre O3 100.1 ± 12.1 102.1 ± 12.7 101.2 ± 12.1 96.8 ± 12
 % predicted FEV1 - post O3 83.8 ± 13* 84.2 ± 13.3* 87.1 ± 9.0* 80.8 ± 15.6*
 PMN counts - pre O3 564 ± 736 470 ± 660 560 ± 780 680 ± 860
 PMN counts - post O3 928 ± 992* 720 ± 710 920 ± 1140 1160 ± 1170
*
p<0.05 versus pre O3. NV = healthy normal volunteers, AR = atopic nonasthmatics (allergic rhinitis), AA = atopic asthmatics, O3 = ozone, PMN
= neutrophil (polymorpholeukocyte).
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